Four paradigms of clinical research and research oversight

Cambridge Quarterly of Healthcare Ethics

Volumn 16, Issue 1, 2007, Pages 82-96

  Emanuel, Ezekiel J ^a   Grady, Christine ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL (TOPIC); ETHICS; HISTORY; HUMAN; MEDICAL ETHICS; PATERNALISM; RESEARCH ETHICS; REVIEW; UNITED STATES;

CLINICAL TRIALS AS TOPIC; ETHICS, MEDICAL; ETHICS, RESEARCH; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; PATERNALISM; UNITED STATES;

EID: 33947370886     PISSN: 09631801     EISSN: 14692147     Source Type: Journal    
DOI: 10.1017/S0963180107070090     Document Type: Review

References (85)

1. Lilienfeld AM. Ceteris paribiis: The evolution of the clinical trial. Bulletin of the History of Medicine 1982;56:1-18;
2. Bull JP. The historical development of clinical therapeutic trials. Journal of Chronic Diseases 1959;10:218-48.
3. Rothman D. Ethical and social issues in the development of new drugs and vaccines. Bulletin of the New York Academy of Science. 1987;63(6):557-68.
4. Halpern SA. Lesser Harms: The Morality of Risk in Medical Research. Chicago, IL: University of Chicago Press; 2004.
5. Howard-Jones N. Human Experimentation and Medical Ethics. Geneva: World Health Organization; 1982.
6. See note 1, Lilienfeld 1982; Bean WB. The Fielding H. Garrison lecture: Walter Reed and the ordeal of human experiments. Bulletin of the History of Medicine 1977;51:75-92;
7. Lederer S. Subjected to Science: Human Experimentation in America before the Second World War. Baltimore: Johns Hopkins University Press; 1997.
8. See note 5, Lederer 1997:22.
9. U.S. Food and Drug Administration. History of the FDA: The 1938 Food, Drug, and Cosmetic Act. Available at: http://www.fda.gov/oc/history/ historyoffda/section2.html.
10. Edgar H, Rothman D. New rules for new drugs: The challenge of AIDS to the regulatory process. The Milbank Quarterly 68 (suppl. 1):111-42.
11. Kuhn TS. The Structure of Scientific Revolutions. Chicago, IL: University of Chicago Press; 1962.
12. See note 3, Halpern 2004.
13. Altman L. Who Goes First? The Story of Self Experimentation in Medicine. New York: Random House; 1987.
14. Rothman D. Ethics and human experimentation - Henry Beecher revisited. New England Journal of Medicine 1987;317:1195-9.
15. Arno P, Feiden K. Against the Odds: The Story of AIDS Drug Development, Politics, and Profits. New York: Harper-Coiling Publishers, Inc.; 1992.
16. Jonas H. Philosophical reflections on experimenting with human subjects. Daedalus 1969;98:219-47.
17. See note 14, Jonas 1969:232.
18. McDermott W. Opening comments. The changing mores of biomedical research. Annals of Internal Medicine 1967;67(suppl. 7):39-42.
19. Lasagne L. Some ethical problems in clinical research. In: Mendelsohn E, Swazey JP, Taviss I, eds. Human Aspects of Biomedical Innovation. Cambridge, Mass.: Harvard University Press; 1971:98-110, at 108, 110.
20. See note 3, Halpern 2004;
21. see note 16, McDermott 1967;
22. see note 17, Lasagna 1971.
23. Beecher H. Ethics and clinical research. New England Journal of Medicine 1966;274:1354-60.
24. See note 19, Beecher 1966:1360.
25. Natanson v. Kline 350 P.2d 1093 (Kan. 1960).
26. Oken D. What to tell cancer patients: A study of medical attitudes. JAMA 1961;175:1120-8.
27. Katz J. The Silent World of Doctor and Patient. New York: The Free Press; 1984:ch. 1-3.
28. See note 19, Beecher 1966;
29. Jones J. Bad Blood: The Tuskegee Syphilis Experiment. New York: The Free Press; 1981, 1993.
30. Brandt A. Racism and research: The case of the Tuskegee Syphilis Study. Hastings Center Report 1978;8(6):21-9.
31. See note 19, Beecher 1966;
32. see note 24, Jones;
33. see note 24, Brandt 1978.
34. See note 24, Jones;
35. see note 24, Brandt 1978.
36. Beecher H. Experimentation in man. JAMA 1959;169(5):461-78, at 468.
37. National Research Act of 1974, Pub. L. No. 348, 93d Cong., 2d Sess. (Jul 12, 1974); Advisory Committee on Human Radiation Experiments. Human Radiation Experiments: Final Report of the President's Advisory Committee. New York: Oxford University Press; 1996:ch. 3.
38. Public Welfare, 45 C. F. R., part 46 (2205). Available at: http://www.hhs.gov/ohrp/humansubjects/guidance /45cfr46.htm.
39. Public Welfare, 45 C. F. R., part 46, Subparts B, C, and D (2205). Available at: http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm; The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research on the Fetus: Report and Recommendations. Washington, DC: U.S. Government Printing Office; 1975;
40. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research Involving Prisoners: Report and Recommendations. Washington, DC: U.S. Government Printing Office; 1976;
41. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Research Involving Children: Report and Recommendations. Washington, DC: U.S. Government Printing Office; 1977.
42. The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Institutional Review Boards: Report and Recommendations. Washington, DC: U.S. Government Printing Office; 1978.
43. Fletcher J. The evolution of the ethics of informed consent. In: Berg K, Tranoy K, eds. Research Ethics. New York: Alan Liss Inc.; 1983:187-228.
44. See note 28, Advisory Committee 1996;
45. see note 31, National Commission 1978.
46. Beauchamp T, Childress J. Principles of Biomedical Ethics. 1st ed. New York: Oxford University Press; 1979.
47. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Principles and Guidelines for the Protection of Human Subjects of Research. Washington DC: U.S. Government Printing Office; 1979.
48. See note 35, National Commission 1979.
49. See note 30, Public Welfare 2005;
50. see note 30, National Commission 1976.
51. See note 30, Public Welfare 2005;
52. see note 30, National Commission 1975.
53. See note 23, Katz 1984;
54. Berg JW, Applebaum PS, Lidz CW, Parker LS. Informed Consent: Legal Theory and Clinical Practice, 2nd ed. New York: Oxford University Press; 2001.
55. Veatch R. A Theory of Medical Ethics. New York: Oxford University Press; 1981:81,97.
56. See note 39, Berg 2001;
57. Cantebury v. Spence 464 F.2d 772 (D.C. Cir. 1972).
58. See note 39, Berg 2001;
59. see note 41, Cantebury v. Spence 1972.
60. Lipsett M. On the nature and ethics of Phase 1 oncology trials of cancer chemotherapy. JAMA 1982;248(8):941-2, at 942.
61. See note 13, Arno, Feiden 1992.
62. Delaney M. The case for patient access to experimental therapy. Journal of Infectious Diseases 1989;159:416-9.
63. National Research Council. The Social Impact of AIDS in the United States. Washington, DC: National Academy Press; 1993.
64. See note 45, Delaney 1989.
65. See note 13, Arno, Feiden 1992. AMFar is the American Foundation for AIDS Research; CPCRA is Community Programs for Clinical Research in AIDS; NIAID is the National Institute of Allergy and Infectious Diseases.
66. See note 45, Delaney 1989:416.
67. NIH guidelines for the inclusion of women and minorities as subjects in clinical research. NIH Guide to Grants and Contracts. March 18, 1994;
68. NIH policy and guidelines on the inclusion of children as participants in research involving human subjects. NIH Guide to Grants and Contracts. March 6, 1998.
69. AMA Council on Ethical and Judicial Affairs. Code of Ethics. Professionalism: E-2.072 Subject Selection for Clinical Trials. Available at http://www.ama-assn.org/ama/pub/category/8423.html; accessed 12 Oct 2006.
70. See note 45, Delaney 1989.
71. Weijer C, Goldsand G, Emanuel EJ. Protecting communities in research: Current guidelines and limits of extrapolation. Nature Genetics 1999;23:275-80;
72. Weijer C, Emanuel EJ. Protecting communities in biomedical research. Science 2000;289:1142-4.
73. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency vims in developing countries. New England Journal of Medicine 1997;337:853-6;
74. Angell M. The ethics of clinical research in the third world. New England Journal of Medicine 1997;337:847-9.
75. Levine RJ. The "best proven therapeutic method" standard in clinical trials in technologically developing countries. IRB 1998;20(1):5-9;
76. Crouch RA, Arras JD. AZT trials and tribulations. Hastings Center Report 1998;28(6):26-34;
77. Grady C. Science in the service of healing. Hastings Center Report 1998;28(6):34-8;
78. Cleaton-Jones PE. An ethical dilemma: Availability of antiretro viral therapy after clinical trials with HIV infected patients are ended. British Medical Journal 1997;314:887-8;
79. Wilmshurst P. Scientific imperialism: tf they won't benefit from the findings, poor people in the developing world shouldn't be used in research. British Medical journal 1997;314:840-1;
80. Glantz LH, Annas GJ, Grodin MA, Mariner WK. Research in developing countries: Taking "benefit" seriously. Hastings Center Report 1998;28(6):38-42;
81. Annas GJ, Grodin MA. Human rights and maternal-fetal HIV transmission prevention trials in Africa. American Journal of Public Health 1998;88:560-62;
82. Shapiro H, Meslin E. The ethics of international research. New England Journal of Medicine 2001;314:139-42.
83. Emanuel E, Wendler D, Killen J, Grady C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. Journal of Infectious Diseases 2004;189:930-7.
84. See note 46, National Research Council 1993.
85. U.S. Food and Drug Administration. Guidance for institutional review boards, clinical investigators, and sponsors: Exception from informed consent requirements for emergency research. Available at: http://www.fda.gov/ora/ compliance_ref/bimo/err_guide.htm.